Decreased circulating levels of α-klotho is also characteristic of patients with CKD and potential therapeutic benefits of targeting α-klotho-dependent actions include increasing circulating levels of calcitriol, decreasing renal fibrosis, and improving bone mineralization and osteoblast function. The gene discussed is KL; the disease is renal fibrosis.